abs241.txt	background		radical	cystectomy	is	the	surgical	standard	for	invasive	bladdercancer	robot-assisted	has	been	proposed	to	provide	similaroncological	outcomes	with	lower	morbidity	we	aimed	compare	progression-freesurvival	in	patients	bladder	cancer	treated	open	androbot-assisted	methods	razor	study	a	randomised	open-label	non-inferiority	phase	3trial	done	15	medical	centres	usa	eligible	participants	(aged	≥18years)	had	biopsy-proven	clinical	stage	t1-t4	n0-n1	m0	orrefractory	carcinoma	situ	individuals	who	previously	abdominalor	pelvic	surgery	or	any	pre-existing	health	conditions	that	wouldpreclude	safe	initiation	maintenance	of	pneumoperitoneum	were	excluded	centrally	assigned	(1	1)	via	web-based	system	blockrandomisation	by	institution	stratified	type	urinary	diversion	tstage	and	eastern	cooperative	oncology	group	performance	status	receiverobot-assisted	extracorporealurinary	treatment	allocation	was	only	masked	from	pathologists	theprimary	endpoint	2-year	progression-free	survival	non-inferiorityestablished	if	bound	one-sided	97·5%	ci	treatmentdifference	(robotic	minus	cystectomy)	greater	than	-15percentage	points	primary	analysis	per-protocol	population	safety	assessed	same	this	trial	registered	withclinicaltrials	gov	number	nct01157676	findings	between	july	1	2011	nov	18	2014	350	randomlyassigned	intended	robotic	176patients	174	17	(10%)	176	therobotic	did	not	have	nine	(5%)	adifferent	they	21	(12%)	theopen	one	(1%)	patient	roboticcystectomy	instead	thus	302	(150	152	group)	included	theper-protocol	set	72·3%	(95%	ci64·3	78·8)	71·6%	63·6	78·2)	inthe	(difference	0·7%	95%	-9·6%	10·9%	pnon-inferiority=0·001)	indicating	adverse	events	occurred	101	(67%)	150	cystectomygroup	105	(69%)	most	commonadverse	tract	infection	(53	[35%]	vs	39	[26%]	postoperative	ileus	(33	[22%]in	31	[20%]	interpretation	wasnon-inferior	increasedadoption	practice	should	lead	future	randomisedtrials	assess	true	value	approach	othercancer	types	funding	national	institutes	institute
